Reduced SIRT2 correlates with higher-grade cancers, poorer PSA recurrence-free survival, and diminished responses to ARSIs, underscoring its potential as a therapeutic target in tumors characterized by heightened p300 activity and histone hyperacetylation. Here, SIRT2 is linked to cancer.